State Street’s Liminatus Pharma LIMN Stock Holding History

State Street’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.1K	Hold	380	–	–	﹤0.01%	4259
2026 Q1	$3.27K	Hold	380	–	–	﹤0.01%	4265
2025 Q4	$11.6K	Hold	380	–	–	﹤0.01%	4265
2025 Q3	$31.7K	Hold	380	–	–	﹤0.01%	4209
2025 Q2	$212K	Buy	+380	New	+$213K	﹤0.01%	3815

Other funds holding LIMN

CCA

Cygnus Capital Advisors Atlanta, Georgia $147M AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

State Street's LIMN Position: Q2 2026 in Review

State Street held its Liminatus Pharma (LIMN) position steady in Q2 2026 at 380 shares worth $2.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4259.

State Street first reported a position in LIMN in Q2 2025 and has held it in 5 quarters since. The position peaked at $212K in Q2 2025. 14 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

State Street held 380 shares of Liminatus Pharma worth $2.1K as of Q2 2026.
State Street left its Liminatus Pharma share count unchanged in Q2 2026.
Liminatus Pharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4259 holding.
State Street first reported a position in Liminatus Pharma in Q2 2025 and has held it in 5 quarters since.
State Street's Liminatus Pharma position peaked at $212K in Q2 2025.
14 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.